HCW Biologics to Execute 1-for-6 Reverse Split to Comply with Nasdaq Rules
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
HCW Biologics reported that the Nasdaq Hearings Panel of Nasdaq found that the company regained compliance with Listing Rule 5550, the "Bid Price Rule," per the terms set forth in the Panel's decision letter dated May 29 as amended, and is subject to a mandatory monitoring period through June 17, 2027. To ensure long-term compliance with the bid price rule, the company will effect a reverse stock split at a one-for-six ratio on June 30.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCWB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCWB
Wall Street analysts forecast HCWB stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.620
Low
8.00
Averages
8.00
High
8.00
Current: 4.620
Low
8.00
Averages
8.00
High
8.00
About HCWB
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HCW Biologics Regains Nasdaq Compliance
- Compliance Restoration: HCW Biologics (HCWB) has regained compliance with Nasdaq's minimum bid price requirement, indicating a restoration of the company's stability in the market, which is likely to enhance investor confidence.
- Monitoring Period Extension: The company will remain under a mandatory Nasdaq monitoring period until June 17, 2027, a measure aimed at ensuring ongoing compliance and reducing future violation risks.
- Reverse Stock Split Plan: To support long-term compliance, HCW Biologics plans to implement a 1-for-6 reverse stock split effective June 30, 2026, which is expected to increase the stock price and enhance market appeal.
- Hearing Panel Decision: This compliance determination follows the Nasdaq Hearings Panel's decision on June 29, 2026, reflecting the company's efforts towards compliance and the recognition from regulatory authorities.
See More
HCW Biologics Announces 1-for-6 Reverse Stock Split
- Reverse Stock Split Announcement: HCW Biologics has announced a 1-for-6 reverse stock split effective June 30, 2026, aimed at meeting Nasdaq Hearings Panel requirements to maintain its listing status.
- Share Capital Changes: Post-split, the outstanding shares will decrease from 9.58 million to approximately 1.60 million, while the authorized share count and par value will remain unchanged, which is intended to elevate the stock price to meet Nasdaq's minimum requirements.
- Trading Adjustments: The reverse split will take effect at 12:01 a.m. Eastern Time on June 30, with shares trading on a split-adjusted basis under the existing ticker symbol “HCWB,” ensuring consistency for investors.
- Market Reaction: HCWB is currently trading at $1.05, down 6.25%, and the reverse stock split may influence market expectations regarding the company's future performance, particularly in the context of maintaining its listing status.
See More
HCW Biologics Approved for 1-for-6 Reverse Stock Split
- Reverse Stock Split Decision: HCW Biologics has announced a 1-for-6 reverse stock split to comply with Nasdaq Listing Rule 5550(a), aiming to avoid immediate delisting risks.
- Compliance Pathway: Following a decision letter from the Nasdaq Hearings Panel on May 29, the company was required to maintain its stock price above $1 for 20 trading days prior to July 29, which it achieved by June 12.
- Share Changes: Post-split, the number of outstanding shares will decrease from 9,581,079 to approximately 1,596,849, while the total authorized shares will remain at 250 million, with a par value of $0.0001 per share.
- Market Reaction: Following the announcement of the reverse stock split, HCWB shares fell by 22.64% in pre-market trading to $0.86, indicating a negative market response to the decision.
See More
HCW Biologics Implements Reverse Stock Split to Ensure Nasdaq Compliance
- Reverse Stock Split: HCW Biologics announced a 1-for-6 reverse stock split effective June 30, 2026, aimed at ensuring compliance with Nasdaq's minimum bid price rule to avoid delisting risks.
- Compliance Progress: The company met the requirement of trading above $1.00 per share for 20 consecutive trading days as of June 12, 2026, demonstrating stock price stability that supports its Nasdaq listing.
- Share Count Adjustment: Post-split, HCW Biologics will reduce its outstanding shares from 9,581,079 to approximately 1,596,849, while maintaining a total authorized share count of 250 million, ensuring capital structure stability.
- Shareholder Impact: The split will uniformly affect all shareholders, with any fractional shares converted into whole shares, thereby protecting shareholder interests and enhancing investor confidence.
See More
HCW Biologics Regains Full Rights to HCW9206 and HCW9201 Compounds
- Rights Reversion: HCW Biologics has exercised its option to regain full ex vivo rights to HCW9206 and HCW9201, two commercially-ready compounds, marking a strategic shift for the company in the cell therapy sector.
- Cost-Free Acquisition: The company acquired these rights from its licensee Wugen Inc. at no cost while retaining a nonrefundable upfront license fee, including 2.2 million shares of Wugen common stock, demonstrating flexibility in asset management.
- Commercialization Strategy: HCW Biologics plans to commercialize these reagents through corporate partners focused on CAR-T and NK-cell therapies, which is expected to drive future revenue growth and enhance market competitiveness.
- Market Reaction: HCW Biologics shares fell 2.7% in premarket trading, indicating that the market's response to this rights reversion may be influenced by short-term uncertainties.
See More
E.F. Hutton Secures $4 Million Financing for HCW Biologics
- Financing Overview: E.F. Hutton & Co. acted as the sole placement agent in securing a $4 million private placement for HCW Biologics, which closed on May 21, 2026, marking a significant advancement for the company in the clinical-stage biopharmaceutical sector.
- Clear Use of Proceeds: HCW Biologics intends to utilize the proceeds from the financing to continue clinical trials for HCW9302, advance IND-enabling studies for its T-Cell Engager HCW11-018b and second-generation immune checkpoint inhibitor HCW11-040, as well as for general corporate purposes, including debt repayment.
- Innovative Treatment Potential: Focused on developing fusion immunotherapeutics for diseases driven by chronic inflammation, CEO Joseph T. Rallo noted that the company's proprietary therapeutics have the potential to fundamentally change the treatment landscape for proinflammatory and senescence-associated diseases, improving patient quality of life and potentially extending longevity.
- Strategic Partnership Outlook: The collaboration between E.F. Hutton and HCW Biologics not only showcases its expertise in biopharmaceutical financing but also underscores its commitment to supporting the company in achieving its clinical and strategic objectives, further solidifying its position in the global investment banking market.
See More
HCW Biologics Regains Nasdaq Compliance
- Compliance Restoration: HCW Biologics (HCWB) has regained compliance with Nasdaq's minimum bid price requirement, indicating a restoration of the company's stability in the market, which is likely to enhance investor confidence.
- Monitoring Period Extension: The company will remain under a mandatory Nasdaq monitoring period until June 17, 2027, a measure aimed at ensuring ongoing compliance and reducing future violation risks.
- Reverse Stock Split Plan: To support long-term compliance, HCW Biologics plans to implement a 1-for-6 reverse stock split effective June 30, 2026, which is expected to increase the stock price and enhance market appeal.
- Hearing Panel Decision: This compliance determination follows the Nasdaq Hearings Panel's decision on June 29, 2026, reflecting the company's efforts towards compliance and the recognition from regulatory authorities.
See More
HCW Biologics Announces 1-for-6 Reverse Stock Split
- Reverse Stock Split Announcement: HCW Biologics has announced a 1-for-6 reverse stock split effective June 30, 2026, aimed at meeting Nasdaq Hearings Panel requirements to maintain its listing status.
- Share Capital Changes: Post-split, the outstanding shares will decrease from 9.58 million to approximately 1.60 million, while the authorized share count and par value will remain unchanged, which is intended to elevate the stock price to meet Nasdaq's minimum requirements.
- Trading Adjustments: The reverse split will take effect at 12:01 a.m. Eastern Time on June 30, with shares trading on a split-adjusted basis under the existing ticker symbol “HCWB,” ensuring consistency for investors.
- Market Reaction: HCWB is currently trading at $1.05, down 6.25%, and the reverse stock split may influence market expectations regarding the company's future performance, particularly in the context of maintaining its listing status.
See More
HCW Biologics Approved for 1-for-6 Reverse Stock Split
- Reverse Stock Split Decision: HCW Biologics has announced a 1-for-6 reverse stock split to comply with Nasdaq Listing Rule 5550(a), aiming to avoid immediate delisting risks.
- Compliance Pathway: Following a decision letter from the Nasdaq Hearings Panel on May 29, the company was required to maintain its stock price above $1 for 20 trading days prior to July 29, which it achieved by June 12.
- Share Changes: Post-split, the number of outstanding shares will decrease from 9,581,079 to approximately 1,596,849, while the total authorized shares will remain at 250 million, with a par value of $0.0001 per share.
- Market Reaction: Following the announcement of the reverse stock split, HCWB shares fell by 22.64% in pre-market trading to $0.86, indicating a negative market response to the decision.
See More
HCW Biologics Implements Reverse Stock Split to Ensure Nasdaq Compliance
- Reverse Stock Split: HCW Biologics announced a 1-for-6 reverse stock split effective June 30, 2026, aimed at ensuring compliance with Nasdaq's minimum bid price rule to avoid delisting risks.
- Compliance Progress: The company met the requirement of trading above $1.00 per share for 20 consecutive trading days as of June 12, 2026, demonstrating stock price stability that supports its Nasdaq listing.
- Share Count Adjustment: Post-split, HCW Biologics will reduce its outstanding shares from 9,581,079 to approximately 1,596,849, while maintaining a total authorized share count of 250 million, ensuring capital structure stability.
- Shareholder Impact: The split will uniformly affect all shareholders, with any fractional shares converted into whole shares, thereby protecting shareholder interests and enhancing investor confidence.
See More
HCW Biologics Regains Full Rights to HCW9206 and HCW9201 Compounds
- Rights Reversion: HCW Biologics has exercised its option to regain full ex vivo rights to HCW9206 and HCW9201, two commercially-ready compounds, marking a strategic shift for the company in the cell therapy sector.
- Cost-Free Acquisition: The company acquired these rights from its licensee Wugen Inc. at no cost while retaining a nonrefundable upfront license fee, including 2.2 million shares of Wugen common stock, demonstrating flexibility in asset management.
- Commercialization Strategy: HCW Biologics plans to commercialize these reagents through corporate partners focused on CAR-T and NK-cell therapies, which is expected to drive future revenue growth and enhance market competitiveness.
- Market Reaction: HCW Biologics shares fell 2.7% in premarket trading, indicating that the market's response to this rights reversion may be influenced by short-term uncertainties.
See More
E.F. Hutton Secures $4 Million Financing for HCW Biologics
- Financing Overview: E.F. Hutton & Co. acted as the sole placement agent in securing a $4 million private placement for HCW Biologics, which closed on May 21, 2026, marking a significant advancement for the company in the clinical-stage biopharmaceutical sector.
- Clear Use of Proceeds: HCW Biologics intends to utilize the proceeds from the financing to continue clinical trials for HCW9302, advance IND-enabling studies for its T-Cell Engager HCW11-018b and second-generation immune checkpoint inhibitor HCW11-040, as well as for general corporate purposes, including debt repayment.
- Innovative Treatment Potential: Focused on developing fusion immunotherapeutics for diseases driven by chronic inflammation, CEO Joseph T. Rallo noted that the company's proprietary therapeutics have the potential to fundamentally change the treatment landscape for proinflammatory and senescence-associated diseases, improving patient quality of life and potentially extending longevity.
- Strategic Partnership Outlook: The collaboration between E.F. Hutton and HCW Biologics not only showcases its expertise in biopharmaceutical financing but also underscores its commitment to supporting the company in achieving its clinical and strategic objectives, further solidifying its position in the global investment banking market.
See More
